On March 4, 2024, Akero Therapeutics unveiled exciting findings from the HARMONY Phase 2B trial of Efruxifermin for pre-cirrhotic metabolic dysfunction-associated steatohepatitis.
___
The results revealed remarkable progress in fibrosis, with EFX treatment groups showcasing a significant ≥1 stage enhancement in fibrosis without MASH deterioration, surpassing the placebo group by three- and two-fold.
___
Moreover, the EFX groups exhibited a remarkable ≥2 stage enhancement in fibrosis without MASH worsening, exceeding the placebo rate by over 10 times. Patients receiving EFX treatment experienced notable enhancements in various histological endpoints and NASH resolution.
AKRO Stock Shows Positive Momentum with 3.04% Rise and Strong Pre-Market Performance on March 4, 2024
On March 4, 2024, AKRO stock showed positive price momentum as it traded in the middle of its 52-week range and below its 200-day simple moving average. The stock price had increased by $0.82 since the market last closed, representing a 3.04% rise from the previous closing price of $27.81.
In pre-market trading, AKRO stock continued to show strong performance as it rose by $17.77. This significant increase in pre-market trading indicated that investors were optimistic about the stock’s potential for growth.
AKRO Stock Performance Analysis: Mixed Results on March 4, 2024
On March 4, 2024, AKRO stock experienced mixed performances based on the financial data available. According to CNN Money, AKRO reported a net income of -$151.76 million over the past year, representing a 35.46% decrease compared to the previous year. In the fourth quarter, the company’s net income improved slightly to -$55.19 million, but still remained in negative territory. Earnings per share (EPS) is another important metric to consider when evaluating a company’s performance. AKRO reported an EPS of -$2.89 over the past year, which represents a 0.46% increase compared to the previous year. However, in the fourth quarter, the company’s EPS decreased significantly to -$0.99, marking a 38.9% decline compared to the previous quarter. Overall, AKRO’s financial performance on March 4, 2024, showed some mixed results. Investors and analysts will likely keep a close eye on AKRO’s future financial reports to assess whether these trends continue or if the company is able to turn things around.
